Lifecore Biomedical Inc. Common Stock (LFCR)

About LFCR

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes,…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

382

Website

www.lifecore.com/

Fundamentals

1-day range

$4.47$4.65

Market cap

$164.67M

P/E (trailing)

—

P/E (forward)

-5.82

EPS (trailing)

$-1.31

Dividend yield

—

Beta

1.08

Avg. volume

176.9K

Forecasts

3 analyst ratings

Lifecore Biomedical Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• LFCR

  Lifecore Biomedical Inc. Common Stock

  $4.58

  ▲ 0.88%
  Market cap $164.67MP/E —
  $3.63$8.98
• OKUR

  OnKure Therapeutics Inc. Class A Common Stock

  $3.78

  ▼ 1.31%
  Market cap $162.39MP/E —
  $2.23$5.38
• TNXP

  Tonix Pharmaceuticals Holding Corp. Common Stock

  $13.59

  ▲ 0.18%
  Market cap $170.01MP/E —
  $9.4$34.04
• ARCT

  Arcturus Therapeutics Holdings Inc. Common Stock

  $15.19

  ▼ 6.06%
  Market cap $170.54MP/E —
  $5.5$24.17
• EVO

  Evotec SE American Depositary Shares

  $1.91

  ▼ 2.80%
  Market cap $172.06MP/E —
  $3.18$7.3
• AARD

  Aardvark Therapeutics Inc. Common Stock

  $5.71

  ▼ 13.75%
  Market cap $154.94MP/E —
  $3.35$17.94
• KRRO

  Korro Bio Inc. Common Stock

  $12.94

  ▼ 2.41%
  Market cap $154.90MP/E —
  $5.2$55.89

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/5/2026
• Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate
  Benzinga · 8/5/2026
• Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.176M Est
  Benzinga · 8/5/2026

• Legion Partners, L.P. I · June 4, 2026 · Grant

  25.9K
• Paul Harold Johnson · June 4, 2026 · Grant

  25.9K
• Humberto Calheiros Antunes · June 4, 2026 · Grant

  25.9K
• Matthew E. Korenberg · June 4, 2026 · Grant

  25.9K
• Jason Aryeh · June 4, 2026 · Grant

  25.9K
• Joshua Schechter · June 4, 2026 · Grant

  25.9K
• Lovas Katrina Houde · June 4, 2026 · Grant

  25.9K
• Nelson Obus · June 4, 2026 · Grant

  25.9K
• Paul Josephs · May 20, 2026 · Tax Withholding

  40.4K @ $4.57
• Thomas D. Salus · April 14, 2026 · Tax Withholding

  24.6K @ $5.2
• Thomas D. Salus · March 2, 2026 · Grant

  30.0K

Institutional Ownership

March 31, 2026

Total shares held

24.76M

Total value held

$110.33M

Institutional holders

102